561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
RAPT Therapeutics Announces Underwritten Public Offering of 8.33M Shares
Investor Presentation
Earnings Release
Changes in Board, Management or Compensation
Amendments to Articles of Incorporation or Bylaws
Reg. FD
Material disclosure
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership